Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, and Advent BioServices, a contract development and manufacturing organization (CDMO) based in the UK, jointly announce that a manufacturer’s importation authorization (MIA) license has been approved and issued by the Medicines and Healthcare Products Regulatory Agency (MHRA) for commercial manufacturing of cell therapy products at the GMP facility in Sawston, UK.
Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB